| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
MAO-B-IN-9 targets monoamine oxidase B (MAO-B), a flavoenzyme located on the outer mitochondrial membrane that catalyzes the oxidative deamination of biogenic amines. MAO-B is primarily involved in the metabolism of dopamine and other neurotransmitters. Inhibition of MAO-B increases dopamine levels in the brain and is a therapeutic strategy for neurodegenerative diseases such as Parkinson's disease. The compound has an IC50 of 0.18 μM for MAO-B and is selective, irreversible, and time-dependent. It is BBB-permeable, making it suitable for CNS applications.
|
|---|---|
| ln Vitro |
In vitro, MAO-B-IN-9 inhibits MAO-B with an IC50 of 0.18 μM. It is selective for MAO-B over MAO-A. The compound prevents Aβ1-42-induced neuronal cell death, demonstrating neuroprotective effects. Its neuroprotective mechanism may involve anti-aggregation effects on Aβ1-42, preventing the formation of toxic amyloid aggregates. The compound is irreversible and time-dependent in its inhibition of MAO-B.
|
| ln Vivo |
In vivo, MAO-B-IN-9 is expected to show neuroprotective effects in animal models of neurodegenerative diseases. Its ability to prevent Aβ1-42-induced neuronal cell death suggests potential applications in Alzheimer's disease research. The compound's BBB permeability makes it suitable for central nervous system studies. However, specific in vivo efficacy data for this compound are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for MAO-B-IN-9 typically involve MAO-B activity assays using purified recombinant MAO-B enzyme or rat brain mitochondrial fractions. The assay is performed in 96-well plates with assay buffer (50 mM potassium phosphate pH 7.4). The compound (typically 0.001-100 μM) is pre-incubated with the enzyme for 30 minutes before adding the substrate (e.g., kynuramine or benzylamine). MAO-B activity is measured by fluorescence detection of the oxidation product (4-hydroxyquinoline for kynuramine, excitation 310 nm, emission 400 nm). The IC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for MAO-B-IN-9 use neuronal cell lines such as SH-SY5Y or primary cortical neurons. Cells are cultured in DMEM/F12 with 10% FBS and treated with various concentrations of the compound (typically 0.01-10 μM) for 4-24 hours. Neuroprotection is assessed by exposing cells to Aβ1-42 peptide (10 μM) for 24-48 hours and measuring cell viability using MTT or LDH assays. Neurite outgrowth and synaptic markers can be assessed by immunocytochemistry. MAO-B activity in cell lysates is measured using a fluorometric assay.
|
| Animal Protocol |
In vivo animal studies with MAO-B-IN-9 would typically use mouse models of Alzheimer's disease or Parkinson's disease. In Aβ injection models, mice are injected intracerebroventricularly with Aβ1-42 and treated with the compound orally or intraperitoneally at doses of 1-30 mg/kg daily for 7-14 days. Cognitive function is assessed by Morris water maze or Y-maze tests. Brain tissue is analyzed for Aβ aggregation, oxidative stress markers, and neurodegeneration. In MPTP-induced Parkinson's disease models, dopamine neuron survival is assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MAO-B-IN-9: The compound is BBB-permeable, indicating good brain penetration. Specific PK parameters such as oral bioavailability, half-life, and tissue distribution are not extensively reported. The compound contains an alkyne group, which may be used for click chemistry applications. It has a molecular weight of 300.4.
|
| Toxicity/Toxicokinetics |
The toxicity profile of MAO-B-IN-9 is not extensively reported in the available literature. As a MAO-B inhibitor, potential side effects may include serotonin syndrome if combined with serotonergic agents. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute toxicity in rodents and assessment of CNS effects.
|
| References | |
| Additional Infomation |
MAO-B-IN-9 (CAS 2416910-88-6, compound 16) is a potent, selective, BBB-permeable, irreversible, time-dependent MAO-B inhibitor with an IC50 of 0.18 μM. It prevents Aβ1-42-induced neuronal cell death and shows neuroprotective effects, possibly through anti-aggregation effects. The compound contains an alkyne group for click chemistry, making it useful for labeling and conjugation studies. It is available for research purposes only.
|
| Molecular Formula |
C18H24N2O2
|
|---|---|
| Molecular Weight |
300.395364761353
|
| Exact Mass |
300.183
|
| CAS # |
2416910-88-6
|
| PubChem CID |
162672044
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
397
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)C1=CC=C(C=C1)NC(=O)OC2CCN(CC2)CC#C
|
| InChi Key |
LJYBWYFQBIECKG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24N2O2/c1-4-11-20-12-9-17(10-13-20)22-18(21)19-16-7-5-15(6-8-16)14(2)3/h1,5-8,14,17H,9-13H2,2-3H3,(H,19,21)
|
| Chemical Name |
(1-prop-2-ynylpiperidin-4-yl) N-(4-propan-2-ylphenyl)carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~332.9 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3289 mL | 16.6445 mL | 33.2889 mL | |
| 5 mM | 0.6658 mL | 3.3289 mL | 6.6578 mL | |
| 10 mM | 0.3329 mL | 1.6644 mL | 3.3289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
